Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Debt to Equity (2020 - 2023)

C4 Therapeutics' Debt to Equity history spans 4 years, with the latest figure at $0.04 for Q2 2023.

  • For Q2 2023, Debt to Equity rose 37.01% year-over-year to $0.04; the TTM value through Jun 2023 reached $0.04, up 37.01%, while the annual FY2022 figure was $0.04, 43.63% up from the prior year.
  • Debt to Equity reached $0.04 in Q2 2023 per CCCC's latest filing, up from $0.04 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.04 in Q2 2023 to a low of -$0.06 in Q3 2020.
  • Average Debt to Equity over 4 years is $0.03, with a median of $0.03 recorded in 2022.
  • The largest YoY upside for Debt to Equity was 141.91% in 2021 against a maximum downside of 22.8% in 2021.
  • A 4-year view of Debt to Equity shows it stood at $0.04 in 2020, then decreased by 22.8% to $0.03 in 2021, then soared by 43.63% to $0.04 in 2022, then rose by 11.4% to $0.04 in 2023.
  • Per Business Quant, the three most recent readings for CCCC's Debt to Equity are $0.04 (Q2 2023), $0.04 (Q1 2023), and $0.04 (Q4 2022).